$EXEL Looks like 9/21/20 for Results "702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study Presentation Number 702O Lecture Time 17:04 - 17:16 Speakers Sumanta Pal (Duarte, United States of America)"
  • 1
1 Like